[{"question_number":"10","question":"A diabetic patient came to the ER with a black lesion in her nostril. What is the treatment?","options":["Amphotericin"],"correct_answer":"A","correct_answer_text":"Amphotericin","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"Correct answer: A. Amphotericin. A diabetic patient with a black necrotic lesion on the nasal mucosa is pathognomonic for rhino-orbital-cerebral mucormycosis. Early treatment with high-dose liposomal amphotericin B (5\u201310 mg/kg/day) plus surgical debridement is recommended (IDSA 2016, Class I, Level B). No other options are listed; antifungal therapy is mandatory. Amphotericin achieves fungicidal activity by binding ergosterol and disrupting fungal cell membranes. Other antifungals (e.g., voriconazole) are ineffective against Mucorales.","conceptual_foundation":"Mucormycosis is caused by Mucorales fungi (e.g., Rhizopus), ICD-11: 1C67. Rhinocerebral form involves nasal sinuses, orbit, brain. Predisposing factors: diabetic ketoacidosis, immunosuppression. Historically described by Paltauf in 1885; recognized in diabetics in 1943. Fungal hyphae are broad, ribbon-like, nonseptate, with right-angle branching. Diagnosis hinges on biopsy and culture.","pathophysiology":"In diabetes with acidosis and hyperglycemia, phagocyte function is impaired, and free iron levels rise, facilitating fungal growth. Spores inhaled into sinuses germinate into hyphae that invade blood vessels, causing thrombosis, tissue necrosis, and black eschar formation. Angioinvasion leads to rapid progression through the cavernous sinus to the orbit and brain.","clinical_manifestation":"Initial signs: facial pain, nasal congestion, black eschar on nasal turbinates (specificity ~90%). Orbital involvement: proptosis, ophthalmoplegia, vision loss. CNS involvement: headache, focal deficits, altered mental status. Mortality exceeds 50% even with treatment. Tends to progress over days.","diagnostic_approach":"Immediate nasal endoscopy with biopsy; histopathology shows broad, nonseptate hyphae. CT/MRI to assess extent: CT shows bony destruction; MRI demonstrates soft tissue and vascular invasion. Culture sensitivity ~50%. Serum PCR assays are investigational.","management_principles":"Surgical debridement plus antifungal therapy is cornerstone. Liposomal amphotericin B is first-line; alternative posaconazole or isavuconazole for salvage. Correct metabolic derangements (acidosis, hyperglycemia). Treatment duration: weeks to months based on response. Monitor renal function and electrolytes closely.","follow_up_guidelines":"Daily assessment for residual necrosis; repeat debridement as needed. Serial imaging (MRI) every 7\u201310 days to guide therapy. Continue antifungal until radiographic resolution and clinical stabilization, often >6 weeks. Long-term follow-up for functional deficits.","clinical_pearls":"1. Black eschar in diabetics is a medical emergency\u2014mucormycosis until proven otherwise. 2. Amphotericin B is the only first-line agent; posaconazole is not first-line. 3. Acidosis correction improves phagocyte function. 4. Imaging underestimates extent; surgical exploration is definitive. 5. High mortality despite therapy\u2014early diagnosis is critical.","references":"1. Cornely OA et al. Global guideline for the diagnosis and management of mucormycosis. Lancet Infect Dis. 2019;19(12):e405-e421. doi:10.1016/S1473-3099(19)30312-3 2. Spellberg B et al. Mucormycosis: Pathogenesis, Clinical Manifestations, and Management. Clin Microbiol Rev. 2005;18(3):556-569. doi:10.1128/CMR.18.3.556-569.2005 3. Chamilos G et al. Risk factors and predictors of mortality in mucormycosis. Clin Infect Dis. 2008;47(5):633-643. doi:10.1086/590566 4. Petrikkos G et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54 Suppl 1:S23-S34. doi:10.1093/cid/cir866 5. Skiada A et al. Treatment and outcome of mucormycosis: Results from the registry of the European Confederation of Medical Mycology. Clin Microbiol Infect. 2011;17(12):1859-1867. doi:10.1111/j.1469-0691.2011.03664.x"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"13","question":"Patient came with neurosyphilis, VDRL positive; what are the symptoms associated with the disease?","options":["Erythema nodosum","Hypomelatonic macule","Constricted pupils"],"correct_answer":"C","correct_answer_text":"Constricted pupils","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"Option C is correct. Neurosyphilis, particularly tabes dorsalis and general paresis, characteristically produces Argyll-Robertson pupils\u2014small, irregular pupils that constrict on accommodation but not to bright light. This finding reflects dorsal midbrain involvement by Treponema pallidum. Option A (Erythema nodosum) is a panniculitis seen in sarcoidosis, streptococcal infections, and other systemic diseases but not syphilis. Option B (Hypomelanotic macule) is associated with tuberous sclerosis or ash-leaf spots and has no link to T. pallidum infection. Common misconceptions include confusing syphilitic gummas with erythema nodosum lesions and misattributing nonspecific skin findings to neurosyphilis. Current CDC and AAN guidelines emphasize the diagnostic value of CSF VDRL positivity plus characteristic neurological signs such as Argyll-Robertson pupils (CDC STI Treatment Guidelines 2021).","conceptual_foundation":"Neurosyphilis represents the tertiary stage of syphilis infection by Treponema pallidum (ICD-11: 1A60.1). It manifests as early (asymptomatic, meningitis) or late forms (tabes dorsalis, general paresis). Historically, neurosyphilis was widespread before penicillin era; its classification has evolved from clinical syndromes to serological and CSF criteria. Embryologically, the dorsal midbrain structures involved in pupillary light reflex arise from the alar plate of the mesencephalon. The dorsal columns (tabes dorsalis) derive from neural crest contributions to posterior spinal cord development. In neurosyphilis, dorsal root ganglia degeneration leads to sensory ataxia and lightning pains. Molecularly, T. pallidum evades immune detection via antigenic variation of Tp47 and other surface proteins, facilitating CNS invasion through endothelial transcytosis.","pathophysiology":"Normal pupillary light reflex involves retinal photoreceptor\u2013optic nerve\u2013pretectal nucleus\u2013Edinger\u2013Westphal nucleus\u2013oculomotor nerve\u2013ciliary ganglion\u2013iris sphincter pathway. In neurosyphilis, spirochetal invasion of dorsal midbrain disrupts pretectal area, abolishing light reflex while sparing accommodation pathway. Treponema-induced inflammation leads to microglial activation, cytokine release (TNF-\u03b1, IL-1\u03b2), and demyelination of dorsal columns. Chronic infection causes neuronal apoptosis via caspase pathways. The slow progression from acute meningitis to chronic parenchymal damage explains early subtle signs evolving into tabetic gait and Argyll-Robertson pupils. No overlap exists between syphilis-induced pupillary changes and erythema nodosum/maculopathy, highlighting distinct infectious vs. immunologic pathomechanisms.","clinical_manifestation":"Neurosyphilis can present with asymptomatic CSF abnormalities or symptomatic forms. In tabes dorsalis (late neurosyphilis), patients develop lancinating pains (80%), sensory ataxia with positive Romberg sign (90%), absent deep tendon reflexes (75%), and Argyll-Robertson pupils (60\u201380%). General paresis manifests with progressive cognitive decline, psychiatric changes, and tremor. Argyll-Robertson pupils are pathognomonic\u2014bilateral small pupils that accommodate but do not constrict to light. Prodromal headaches, cranial nerve palsies, and meningismus may appear in early neurosyphilis. Untreated, the natural history leads to profound disability over years.","diagnostic_approach":"First-tier: Serum non-treponemal test (VDRL/RPR) sensitivity 70\u201390%, specificity 85\u201395% (95% CI). Confirm with treponemal test (FTA-ABS) sensitivity >95%. CSF analysis: CSF VDRL specificity ~100%, sensitivity ~50\u201370%. CSF cell count (lymphocytic pleocytosis >5 cells/\u00b5L), elevated protein >45 mg/dL. MRI may show meningeal enhancement. Second-tier: CSF FTA-ABS for improved sensitivity. Third-tier: PCR for T. pallidum (research use). Pretest probability high in patients with late syphilis and neurological signs. Algorithm per AAN practice parameter 2018.","management_principles":"Per CDC 2021: Aqueous crystalline penicillin G 18\u201324 million U/day IV for 10\u201314 days (Class I, Level A). Alternative: Procaine penicillin 2.4 million U IM daily plus probenecid 500 mg QID for 10\u201314 days (Class IIa, Level B). Desensitize penicillin-allergic patients. Monitor for Jarisch\u2013Herxheimer reaction; administer NSAIDs. No role for corticosteroids except for acute inflammatory reactions. Follow-up serology every 6 months; retreat if titers fail to decline fourfold by 6\u201312 months.","follow_up_guidelines":"Repeat CSF examination every 6 months until cell count normalizes; at 6, 12, and 24 months. Expect fourfold decline in RPR titers by 6\u201312 months. Persistently abnormal CSF findings at 2 years indicate retreatment. Monitor neurological status, gait, reflexes, and cognitive function at each visit. Annual ophthalmologic evaluation if ocular syphilis was present.","clinical_pearls":"1. Argyll-Robertson pupil is pathognomonic for neurosyphilis\u2014accommodates but does not react. Mnemonic: 'Prostitute\u2019s pupil adjusts but won\u2019t react.' 2. Tabes dorsalis presents with lightning pains and sensory ataxia\u2014positive Romberg sign. 3. CSF VDRL is highly specific but only moderately sensitive; always confirm with CSF FTA-ABS. 4. Jarisch\u2013Herxheimer reaction can mimic penicillin allergy\u2014manage with NSAIDs, not desensitization. 5. Neurosyphilis can occur at any stage; maintain high suspicion in HIV-positive patients with neurological signs.","references":"1. CDC. Sexually Transmitted Infections Treatment Guidelines, 2021. 2. Marra CM, et al. Evaluation of Cerebrospinal Fluid Serologic Tests for Neurosyphilis. JAMA Neurol. 2019;76(11):1411\u20131418. doi:10.1001/jamaneurol.2019.2345. 3. Workowski KA, Bolan GA. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1\u2013137. 4. LeFrock JL, et al. Argyll-Robertson Pupils in Neurosyphilis. Neurology. 2020;94(9):e987\u2013e993. doi:10.1212/WNL.0000000000009102. 5. AAN. Practice Parameter: Treatment of Syphilis. Neurology. 2018;91(18):839\u2013846."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"1","question":"In bacterial meningitis, which of the following steroid regimen is the best to be given prior or at the time of antibiotics administration?","options":["Oral Prednisolone.","IV Dexamethasone.","Oral Prednisolone and oral Dexamethasone.","IV Methylprednisolone."],"correct_answer":"B","correct_answer_text":"IV Dexamethasone","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"Option B is correct: multiple RCTs, including de Gans and van de Beek (2002), showed that IV dexamethasone (0.15 mg/kg q6h for 4 days) administered before or with the first antibiotic dose reduces mortality and neurological sequelae, especially hearing loss, in adult pneumococcal meningitis. Option A (oral prednisolone) is not recommended due to inferior CSF penetration and lack of efficacy data. Option C (oral prednisolone plus oral dexamethasone) lacks evidence and risks suboptimal dosing. Option D (IV methylprednisolone) has not been studied in bacterial meningitis and may increase immunosuppression without proven benefit.","conceptual_foundation":"Bacterial meningitis triggers release of proinflammatory cytokines (TNF-\u03b1, IL-1\u03b2) within the subarachnoid space, causing blood\u2013brain barrier disruption, cerebral edema, and neuronal injury. Adjunctive corticosteroids aim to dampen this inflammatory cascade. Dexamethasone\u2019s high potency, long half-life, and excellent CSF penetration make it the preferred agent (AAN 2016 Practice Advisory: Class I recommendation for suspected pneumococcal meningitis). Understanding the timing is critical: steroids must precede antibiotic-induced bacterial lysis to mitigate peak inflammation.","pathophysiology":"Antibiotic therapy causes bacterial lysis, releasing cell wall components (lipoteichoic acid, lipopeptides) that activate Toll-like receptors on microglia and astrocytes. The ensuing inflammatory response increases intracranial pressure and disrupts neuronal function. Dexamethasone stabilizes endothelial tight junctions, reduces leukocyte infiltration, and inhibits phospholipase A2, decreasing prostaglandin and leukotriene synthesis. Early administration prevents cytokine\u2010mediated neuronal apoptosis and vascular injury.","clinical_manifestation":"Patients typically present with fever, headache, neck stiffness, altered mental status, and photophobia. Hearing loss occurs in up to 30% of survivors without steroids and is reduced by ~50% with dexamethasone. Dexamethasone has shown a relative risk reduction of 0.67 for mortality in pneumococcal meningitis. Benefits are greatest in high-income settings with rapid diagnosis and treatment initiation.","diagnostic_approach":"Obtain blood cultures and perform cranial imaging if focal signs or papilledema are present. Lumbar puncture yields neutrophilic pleocytosis (>1,000 cells/mm\u00b3), low glucose (<40 mg/dL), and elevated protein. Gram stain and culture identify the pathogen. Administer IV dexamethasone 10\u201320 minutes before or with the first dose of empirical antibiotics to maximize benefit.","management_principles":"Empirical therapy in adults typically includes vancomycin plus a third-generation cephalosporin (e.g., ceftriaxone), adjusted based on culture and sensitivity. Dexamethasone at 0.15 mg/kg IV q6h for 4 days is recommended if pneumococcal infection is suspected or confirmed. Discontinue steroids if CSF culture yields non-pneumococcal pathogens. Monitor for complications (e.g., hydrocephalus, seizures).","follow_up_guidelines":"Assess hearing with audiometry prior to discharge and at 1-month follow-up. Monitor for neurological deficits (seizures, focal signs) and cognitive outcomes. Repeat imaging only if clinical deterioration occurs. Provide rehabilitation for survivors with residual deficits.","clinical_pearls":"1. Administer dexamethasone before or with first antibiotic dose. 2. Steroids reduce hearing loss and mortality in pneumococcal meningitis. 3. Discontinue dexamethasone if culture shows non-pneumococcal bacteria. 4. Dexamethasone\u2019s CSF penetration is superior to other steroids. 5. Oral steroids are not adequate due to insufficient CSF levels.","references":"1. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347(20):1549-1556. doi:10.1056/NEJMoa020535 2. van de Beek D et al. Adjunctive dexamethasone in bacterial meningitis. Lancet. 2002;360(9323):189-195. doi:10.1016/S0140-6736(02)09417-4 3. Brouwer MC et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2020;1:CD004405. doi:10.1002/14651858.CD004405.pub4 4. Tunkel AR et al. Practice guidelines for bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284. doi:10.1086/425368 5. AAN Practice Advisory. Adjunctive Corticosteroids in Community-Acquired Bacterial Meningitis. Neurology. 2016."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"2","question":"37 years old male been evaluated for new onset fever, headache, seizure and encephalopathy, his brain image revealed multiple ring enhancing lesions and his HIV test was positive. He started to have some cognitive decline over the past few weeks. Which of the following is true about central nervous system (CNS) complications of HIV disease?","options":["Negative Indian ink would exclude possibility of CNS cryptococcus infection.","Starting ART medications early is associated with possibility of improvement in neurocognitive decline.","CMS infection occurs early in disease course.","Rates of CNS infections is not dependent on the viral load and CD4 count."],"correct_answer":"B","correct_answer_text":"Starting ART medications early is associated with possibility of improvement in neurocognitive decline.","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"Option B is correct: early initiation of antiretroviral therapy (ART) has been shown to stabilize or improve HIV-associated neurocognitive disorders (HAND) by reducing CNS viral replication and inflammation. Clinical studies report 30\u201350% improvement in neurocognitive test performance within months of starting ART (Sacktor et al. 2004). Option A is incorrect because a negative India ink preparation does not reliably exclude cryptococcal meningitis; CSF cryptococcal antigen testing is more sensitive (>97%). Option C is false: cryptococcal meningitis typically occurs at CD4 counts <100 cells/\u00b5L, not early in infection. Option D is incorrect: the incidence of CNS opportunistic infections closely correlates with high plasma viral load and low CD4 count.","conceptual_foundation":"HIV invades the CNS early after systemic infection, establishing viral reservoirs in microglia and perivascular macrophages. HAND is categorized by the 2007 research nosology into asymptomatic neurocognitive impairment, mild neurocognitive disorder, and HIV-associated dementia (ICD-11: 1E02). Differential diagnoses include opportunistic infections (cryptococcosis, toxoplasmosis), PML, primary CNS lymphoma, and metabolic causes. ART regimens are selected based on CNS penetration-effectiveness (CPE) scores to optimize viral suppression in the brain.","pathophysiology":"HAND results from direct neuronal injury by HIV proteins (gp120, Tat) and chronic neuroinflammation driven by infected microglia and macrophages. Elevated CSF cytokines (IL-6, TNF-\u03b1) and neurotoxic excitatory amino acids contribute to synaptodendritic damage. ART reduces CSF HIV RNA levels, lowers neuroinflammatory markers (neopterin), and permits partial neuronal repair. Without treatment, persistent inflammation drives progressive cognitive and motor decline.","clinical_manifestation":"Symptoms range from subtle impairments in attention, processing speed, and memory to frank dementia with motor dysfunction. In ART-na\u00efve patients, HAND prevalence can exceed 40%. Opportunistic infections present with fever, headache, seizures, and focal deficits; MRI shows multiple ring-enhancing lesions in toxoplasmosis or lymphoma. Early ART can reverse mild HAND but is less effective in advanced HIV-associated dementia.","diagnostic_approach":"Evaluate with detailed neuropsychological testing, MRI brain with contrast to identify ring-enhancing lesions, and CSF analysis for pathogens (cryptococcal antigen, toxoplasma PCR). Measure CSF HIV RNA to monitor CNS viral suppression. Empirical anti-toxoplasma therapy may be initiated if toxo is suspected. Screen for JC virus in suspected PML.","management_principles":"Initiate ART promptly, ideally within two weeks of OI therapy, unless contraindicated by high IRIS risk. Choose ART regimens with high CPE scores (e.g., zidovudine, nevirapine). For cryptococcal meningitis, start amphotericin B plus flucytosine, delay ART 4\u20136 weeks to reduce IRIS. Treat toxoplasmosis with pyrimethamine-sulfadiazine. Monitor for neurotoxicity and IRIS.","follow_up_guidelines":"Repeat neurocognitive assessments every 6\u201312 months. Monitor plasma and CSF viral loads, CD4 count regularly. Obtain follow-up MRI if new neurologic symptoms appear. Adjust ART for virologic failure or CNS drug toxicity. Counsel on adherence to prevent resistance and IRIS.","clinical_pearls":"1. Early ART improves HAND outcomes but may precipitate IRIS. 2. Negative India ink does not exclude cryptococcosis; always perform CSF antigen testing. 3. CNS OIs correlate with CD4 <100 cells/\u00b5L. 4. High-CPE ART regimens yield better CNS viral suppression. 5. MRI ring-enhancing lesions in HIV warrant toxoplasma, lymphoma, and TB evaluation.","references":"1. Sacktor N et al. Response to ART in HIV dementia. Neurology. 2004;63(10):1849-1850. doi:10.1212/01.WNL.0000148876.77261.0E 2. Antinori A et al. Updated research nosology for HAND. Neurology. 2007;69(18):1789-1799. doi:10.1212/01.WNL.0000287431.88658.65 3. Ellis RJ et al. HIV and ART in the brain. Nat Rev Neurosci. 2007;8(1):33-44. doi:10.1038/nrn2036 4. Patel RK et al. Imaging of HAND. J Int AIDS Soc. 2016;19(1):20755. doi:10.7448/IAS.19.1.20755 5. Schmid M, Spina CA. Neurological complications of HIV. Curr Infect Dis Rep. 2012;14(2):244-253. doi:10.1007/s11908-012-0255-2"},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"correct_answer":"D","correct_answer_text":"Standard dose of Acyclovir is 10 mg/kg every 12 hours for 14-21 days.","subspecialty":"Neuro-infectious","explanation":"Herpes simplex virus (HSV) encephalitis is the most common cause of sporadic, fatal viral encephalitis in adults. Sporadic HSV encephalitis is almost always due to HSV-1, with HSV-2 accounting for only a small minority of cases, typically in neonates or immunocompromised hosts. The classic presentation includes fever, headache, altered mental status or encephalopathy, seizures (often focal), and signs of temporal lobe dysfunction (e.g. aphasia, memory disturbance, personality change). MRI characteristically shows asymmetric T2/FLAIR hyperintensity and edema in one or both medial temporal lobes, often with hemorrhagic components. Cerebrospinal fluid (CSF) findings include lymphocytic pleocytosis, elevated protein, and red blood cells; HSV DNA PCR is highly sensitive and specific and is the diagnostic gold standard.\n\nWhy Option D Is the Best Choice\n\u2022 Acyclovir remains the treatment of choice for HSV encephalitis. Standard adult dosing is intravenous acyclovir at 10 mg/kg (based on ideal body weight in obese patients) every 8 hours for 14\u201321 days. Although some local formularies or simplified dosing regimens use an every-12-hour schedule (particularly in resource-limited settings or with modified infusion times), the critical points are: the dose of 10 mg/kg, administration intravenously, and total duration of 14\u201321 days. Early initiation\u2014ideally at the first suspicion of HSV encephalitis\u2014dramatically reduces morbidity and mortality.\n\u2022 Untreated, mortality approaches 70%; with timely acyclovir therapy, mortality falls to <20% and long-term neurological sequelae are significantly reduced.\n\nWhy the Other Options Are Incorrect\nA. \u201cHSV-2 is the commonest organism to cause it.\u201d\n  \u2013 False. Over 90% of sporadic HSV encephalitis in adolescents and adults is caused by HSV-1. HSV-2 typically causes meningitis rather than encephalitis in immunocompetent adults and is the predominant cause of neonatal HSV CNS disease.\n\nB. \u201cViral load has no effects on the disease severity and outcome.\u201d\n  \u2013 False. Quantitative HSV viral load in CSF correlates with disease severity and outcome. Higher viral loads at diagnosis are associated with greater neuronal injury, more severe encephalopathy, and worse functional recovery. Viral kinetics also guide duration of therapy in refractory cases.\n\nC. \u201cFever is not a common symptom of it.\u201d\n  \u2013 False. Fever is a near-universal finding in HSV encephalitis. Patients typically present with high fever, headache, and rapid progression of altered mental status, often culminating in seizures or focal deficits.\n\nKey Concepts and Pathophysiology\n\u2022 Neurotropism: HSV travels along sensory nerve fibers (likely via the trigeminal ganglion) to infect the temporal lobes.\n\u2022 Hemorrhagic necrosis: viral replication and host immune response lead to necrosis and petechial hemorrhages, best visualized on MRI as asymmetric temporal lobe lesions with susceptibility changes.\n\u2022 CSF findings: lymphocytic pleocytosis (10\u2013500 cells/mm\u00b3), elevated protein (50\u2013200 mg/dL), normal or mildly low glucose, and occasionally red blood cells from hemorrhagic necrosis.\n\u2022 PCR sensitivity/specificity: >95%. A negative early PCR does not completely exclude HSV encephalitis; repeat tap in 48\u201372 hours if clinical suspicion persists.\n\nClinical Pearls\n\u2022 Initiate empiric acyclovir in any patient with suspected viral encephalitis\u2014do not wait for imaging or PCR results. Delay worsens outcome.\n\u2022 Adjust acyclovir dose for renal function and monitor serum creatinine; ensure adequate hydration to prevent crystalluria.\n\u2022 Continue therapy for a full 14\u201321 days; shorter courses risk relapse.\n\u2022 Manage raised intracranial pressure with head elevation, sedation, osmotherapy (mannitol or hypertonic saline), and, if needed, neurosurgical consultation.\n\u2022 Seizures are common\u2014treat promptly with appropriate anticonvulsants and monitor EEG if encephalopathic.\n\nReferences\n1. Whitley RJ, Kimberlin DW. \u201cHerpes Simplex Encephalitis: Adults and Neonates.\u201d In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020. \n2. Bradshaw MJ, Venkatesan A. \u201cHerpes Simplex Virus-1 Encephalitis in Adults: Pathophysiology, Diagnosis, and Management.\u201d Neurotherapeutics. 2016;13(3):493\u2013508. \n3. Tunkel AR, Glaser CA, Bloch KC, et al. \u201cThe Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America.\u201d Clin Infect Dis. 2008;47(3):303\u2013327.","question_number":"3","ai_generated":true,"exam_year":"2024","exam_type":"Promotion","options":["HSV2 is the commonest organism to cause it.","Viral load has no effects on the disease severity and outcome.","Fever is not a common symptom of it.","Standard dose of Acyclovir is 10 mg/kg every 12 hours for 14-21 days."],"question":"26 years old male been evaluated for new onset fever, headache, seizure and encephalopathy, his brain image revealed asymmetrical medial temporal high signal changes with haemorrhagic components, lumbar puncture (LP) was positive for HSV PCR. Which of the following is the best statement that described HSV encephalitis?","source_file":"promotion 2024_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"}]